Holen Sie sich die Stockscreener-App
0.2199
14.97%
-0.0387
Schlusskurs vom Vortag:
$0.2586
Offen:
$0.25
24-Stunden-Volumen:
1.80M
Relative Volume:
0.07
Marktkapitalisierung:
$6.10M
Einnahmen:
$94,000
Nettoeinkommen (Verlust:
$-13.28M
KGV:
-0.0301
EPS:
-7.2965
Netto-Cashflow:
$-11.67M
1W Leistung:
-22.95%
1M Leistung:
-17.33%
6M Leistung:
-82.41%
1J Leistung:
-91.44%
1-Tages-Spanne:
$0.1901
$0.2597
1-Wochen-Bereich:
$0.1901
$0.28
52-Wochen-Spanne:
$0.1901
$2.977
AIM ImmunoTech Inc Stock (AIM) Company Profile
Firmenname
AIM ImmunoTech Inc
Sektor
Branche
Telefon
352 448 7797
Adresse
2117 SW Highway 484, Ocala, FL
Compare AIM vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
0.2199 | 7.13M | 94,000 | -13.28M | -11.67M | -7.2965 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
AIM ImmunoTech Inc Aktie (AIM) Neueste Nachrichten
AIM Stock Soars 42% As Pancreatic Cancer Trial Hits Key Enrollment Milestone Before Schedule — CEO Sees 'Significant Value-Inflection Period' Ahead - Stocktwits
Analysts’ Opinions Are Mixed on These Healthcare Stocks: AIM ImmunoTech (AIM) and Schrodinger (SDGR) - The Globe and Mail
Why Did AIM Stock Plummet 35% Today? - Stocktwits
Maxim Group Maintains AIM ImmunoTech(AIM.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article - The Manila Times
AIM's Ampligen-Treated Mouse Group Had 100% Ebola Survival - Stock Titan
Form 8K AIM ImmunoTech Inc For: 11 August By Investing.com - Investing.com Nigeria
Biodefense is force protection: Ready today, prepared for tomorrow - Breaking Defense
AIM ImmunoTech Releases Q2 2026 Financial Results - AlphaStreet
Form 8K AIM ImmunoTech Inc For: 10 August By Investing.com - Investing.com Australia
AIM ImmunoTech Q2 loss widens to $3.8M, EPS misses estimates - scanx.trade
AIM ImmunoTech Reports Completion of Phase 2 Ampligen Dosing in Metastatic Pancreatic Cancer Trial, Advances Phase 3 Planning - quiverquant.com
AIM ImmunoTech Reports Q2 2026: $9.9M Cash, $3.8M Net Loss - TradingView
AIM Completes Pancreatic Cancer Study Dosing; Phase 3 Planned - Stock Titan
AIM ImmunoTech (NYSE: AIM) returns to positive equity after new financings - Stock Titan
AIM ImmunoTech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
AIM ImmunoTech Inc (AIM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Form 8K AIM ImmunoTech Inc For: 6 August By Investing.com - Investing.com Nigeria
AIM ImmunoTech signs $1.5 million manufacturing agreement with Sterling Pharma - Investing.com
AIM ImmunoTech (AIM) inks $1.5M manufacturing pact for Ampligen - Stock Titan
AIM ImmunoTech (AIM) Climbs 7.98% as Biotech Micro-Cap Tests Key Resistance at $0.29PCR Spike - dars.gov.et
AIM ImmunoTechDuripanc Overall Survival En - Moomoo
AIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point - Yahoo Finance
AIM ImmunoTech Inc (AIM) Institutional Confidence - TradingKey
AIM ImmunoTech Inc (AIM) Cash Flow - TradingKey
AIM|AIM ImmunoTech Inc|Price:0.254|Chg%:+0.005 - TradingKey
AIM ImmunoTech Inc (AIM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
AIM ImmunoTech Inc (AIM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
AIM ImmunoTech Inc (AIM) Balance Sheet - TradingKey
AIM|AIM ImmunoTech Inc|Price:0.241|Chg%:-0.009 - TradingKey
AIM ImmunoTech Inc (AIM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aim Immunotech Inc. (AIM) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Aim Immunotech Inc. (AIM) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
AIM ImmunoTech Inc. Revenue Breakdown – AMEX:AIM - TradingView
Zacks.com featured highlights include AIM ImmunoTech, Hasbro, Fox, Cencora and Intuitive Surgical - Yahoo Finance
AIM ImmunoTech Inc. (AIM) Stock Price, News, Quote & History - Yahoo! Finance Canada
AIM ImmunoTech Inc. (AIM) stock price, news, quote and history - Yahoo Finance Australia
AIM ImmunoTech Q1 2026 Earnings: EPS Misses Estimates as Company Continues Clinical DevelopmentRevenue Report - dars.gov.et
Frontier tech research, news & data - MLQ.ai
AIM ImmunoTech(AIM) Stock Options Chain | Quotes & News - Moomoo
AIM ImmunoTech Stockholders Approve Key Equity Proposals - TipRanks
AIM ImmunoTech Inc. Announces Results of Shareholder Vote and Approves Reverse Stock Split – SEC 8-K Filing Highlights - Minichart
Shareholders at AIM ImmunoTech (NYSE: AIM) approve >19.99% issuances and reverse split - Stock Titan
AIM ImmunoTech shareholders approve stock issuance proposals at special meeting - Bitget
AIM ImmunoTech Q1 2026 Earnings: Wider-than-Expected Loss Highlights R&D Spending Amid Ongoing Pipeline ProgressReturn On Capital - dars.gov.et
AIM News | AIM IMMUNOTECH INC (NYSEARCA:AIM) - ChartMill
AIM Should I Buy - Intellectia AI
AIM ImmunoTech (AIM) Hovers Near Key Resistance Amid Minimal Price MovementFibonacci Retracement - dars.gov.et
AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series - 富途牛牛
AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program - The Manila Times
Finanzdaten der AIM ImmunoTech Inc-Aktie (AIM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):